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Introduction
For religious reasons, Jehovah’s witnesses (JW) refuse
transfusion of any blood product (red cells, platelets,
fresh frozen plasma) that has been removed from conti-
nuity with the body, but they may accept solid organ
transplantation [1]. Kidney [2], pancreas-kidney [3,4],
heart [5], lung [6,7] and liver [8–16] transplants were
reported in JW patients. Liver transplantation (LT) may
be particularly challenging in JW patients. LT requires
large surgical dissections and sutures of major vascular
vessels. Moreover most LT patients are at high risk of
bleeding because of multiple coagulation disturbances
because of cirrhosis and portal hypertension [17]. In
addition LT may require the use of veno-venous bypass
that consumes platelets and coagulation factors. Diffuse
fibrinolysis and disseminated intravascular coagulation
may occur during the anhepatic phase and after liver graft
reperfusion, especially if early graft dysfunction occurs
[17].
Working in a University Hospital offering medical care
to JW with respect of their beliefs, the authors developed
a blood product-free LT program in JW patients and
report their experience in this paper. This approach might
be beneficial for non-JW patients undergoing LT, as
it may help to reduce the perioperative use of blood
products.
Materials and methods
The policy of the authors’ departments and institution
concerning JW patients was approved by the institution
ethical committee, and was also in accord with the official
advice given by the Belgian National Bioethical Council
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Summary
For religious reasons, Jehovah’s witnesses refuse transfusion of blood products
(red cells, platelets, plasma), but may accept organ transplantation. The authors
developed a multidisciplinary protocol for liver transplantation in Jehovah’s
witnesses. In a 6-year period, nine Jehovah’s witness patients were listed for
liver transplantation. They received preoperative erythropoietin therapy, with
iron and folic acid that allowed significant haematocrit increase. Two patients
underwent partial spleen embolization to increase platelet count. Seven patients
underwent cadaveric whole liver transplantation, and two right lobe living-rela-
ted liver transplantation, using continuous circuit cell saving system and high
dose aprotinin. No patient received any blood product during the surgical pro-
cedure. One patient suffering from deep anaemia after living-related liver trans-
plantation was transfused as required by his family, but died from aspergillus
infection. One 6-year-old child was transfused against her parent’s will. The
authors demonstrated that it is possible to increase haematocrit and platelet
levels in cirrhotic patients awaiting liver transplantation. They were able to
reduce intraoperative need for blood products, allowing liver transplantation in
prepared Jehovah’s witness patients. This experience may be beneficial for non-
Jehovah’s witness liver transplant recipients.
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[18]. Adult JW patients are managed in respect of their
beliefs, after signing a written informed consent. For
patients under the age of 18, blood products are avoided
except in case of life threatening conditions in which
blood products may be used, even against parents’ will.
The problems and risk of death linked to the avoidance
of blood products are openly discussed with the JW
patients in a private interview. For LT, it is clearly stated
that there is some remnant blood in the transplanted
graft. Each component of blood is discussed. The JW
patients always refused the cellular parts of blood (red
cells and/or platelets) as well as human coagulation fac-
tors, cryoprecipitates or fresh frozen plasma. Some pro-
teins purified from blood, as albumin or some
immunoglobulins, might be accepted. The authors refuse
to offer LT to JW patients if their regular postoperative
protocols of immunosuppression, or of disease recurrence
prophylaxis may not be used. Particularly, the use of anti
HBs immunoglobulins is required in hepatitis B virus
(HBV) patients.
Between 1998 and 2003, nine JW patients (four males,
five females) were listed for LT and transplanted
(Table 1). Their mean age was 41 years (range:
6–60 years). The patients underwent regular pre LT
work-up, including abdominal computed tomography,
abdominal doppler ultrasonography and cardiac echogra-
phy. Moreover all of the adult candidates underwent
cardiac stress test, even in the absence of cardiovascular
risk factors. A haematocrit of 35% and a platelet level of
50 000 mm3 were considered as the minimal acceptable
levels for LT in JW patients. A medical preparation aim-
ing at increasing haematocrit was undergone preopera-
tively in all patients, consisting of high dose
erythropoietin (Neorecormon, Roche, Basel, Switzerland;
800 U/kg load, 200 U/kg s.c. every other day), iron sup-
plementation (oral, 500 mg/day, Fero-Grad, Abbot, Abbot
Park, IL, USA, and IV, Venofer, Vifor, Switzerland,
100 mg/day three times per week), and folic acid (4 mg/
day, Folavit, Wolfs, Belgium) administration. Percutane-
ous partial spleen embolization was performed if neces-
sary in order to increase platelet level, as described [19].
At least two surgeons experienced in LT were in the
operative room during all procedures. Meticulous haemos-
tasis was achieved using surgical ligatures, uni- and/or
bipolar coagulation, and argon beam coagulation. Cold
and warm ischaemia and operative time were kept min-
imal. High dose aprotinin (Trasylol, Bayer, Germany)
(2 000 000 kallikrein inhibiting unit (KIU) as a loading
dose at induction, followed by continuous infusion of
500 000 KIU/h) was given during LT to limit fibrinolysis.
Continuous circuit cell salvage and reinfusion whereby
scavenged blood was maintained in continuity with the
patient’s circulation, was used in all procedures. Hypother-
mia was limited by the forced use of an air warmer blanket
and blood drawing was kept as minimal as possible.
In cadaveric adult LT, the Belghiti’s technique was used
[20]. Briefly, it is a piggy-back LT with a systematic surgi-
cal, end-to-side, temporary, porto-caval shunt, without
the use of a veno-venous bypass. The caval reconstruction
consists in a large (>5 cm), side-to-side, cavo-caval anas-
tomosis. This technique is the authors’ standard LT pro-
cedure in adults. The 6-year-old child underwent
standard orthotopic LT procedure, with triple (supra hep-
atic vena cava, infra hepatic vena cava, portal vein)
clamping and without bypass, according to the paediatric
surgeon preferences. Marginal cadaveric liver grafts were
not accepted. Two patients underwent a living related
liver transplantation (LRLT) using a right lobe, as des-
cribed [21]. During right lobe harvesting, liver cut surface
haemostasis was achieved by contact radiofrequency (Tis-
sueLink Floating Ball, Tissuelink, Dover, NH). In the
LRLT recipient procedures, 20 lg/kg recombinant activa-
ted factor VII (Novoseven, Novo Nordisk, Denmark) was
injected at the beginning of dissection, and at reperfusion.
During the postoperative period, erythropoietin therapy
was continued, as long as the haematocrit was lower than
Table 1. Characteristics of the patients listed for liver transplantation.
Patient no. Gender Age (years) Liver disease CHILD Status Outcome
1 Male 60 HCV + HCC B LT Alive
2 Male 45 HBV C LT Alive
3 Female 34 PSC A LT Alive
4 Female 50 PBC B LT Alive
5 Female 6 Antitrypsin B LT Alive
6 Female 16 Autoimmune B LRLT Alive
7 Male 60 HBV + HCC C LRLT Deceased
8 Male 53 Idiopathic B LT Alive
9 Female 49 PBC B LT Alive
HBV, hepatitis B virus; HCC, hepatocarcinoma; HCV, hepatitis C virus; PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis; LT, liver
transplantation; LRLT, living related liver transplantation.
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35%. Invasive postoperative procedures were avoided
if possible. Postoperative immunosuppression consisted in
a combination of calcineurin inhibitors (cyclosporin,
Neoral, Novartis, or tacrolimus, Prograft; ProGraft, Astel-
las, Tokyo, Japan), antimetabolites (azathioprine, Imuran,
or mycophenolate mofetil, Cellcept; Roche) and low-dose
steroids (rapidly tapered to be stopped at month 3–6).
Acute rejection was suspected on biological grounds and/or
on liver graft biopsy. First line treatment of acute rejection
consisted in calcineurin inhibitors dosing increase and in
three i.v. administrations of daily 500 mg of methylpredn-
isolone (Solumedrol; Pfizer, New York, NY, USA). The
patients were all regularly seen at the outpatient clinic.
None was lost to follow-up.
Statistical analysis
All results are expressed as mean and standard error of the
mean. One-way anova was used for statistical analysis. A
P-value <0.05 was considered as statistically significant.
Results
Preoperative period
During the preparation and the waiting time period, all
patients received erythropoietin and iron therapy. This
treatment allowed a significant increase of haematocrit,
from 35.5 ± 2.0% to 40.0 ± 2.7% (p < 0.05) at LT. The
platelet level was in the acceptable range for LT, accord-
ing to the critical minimal levels, in all patients but two
whose platelet count was lower than 20 000/mm3. These
two patients underwent partial spleen embolization that
allowed platelet count increase with a maximum level
after 1–2 weeks (Fig. 1). These two patients were subse-
quently successfully transplanted 2 and 12 weeks after
procedure, without complication linked to the spleen
embolization. All but one patient (patient 4) accepted the
use of purified human albumin, and the HBV patients
accepted the use of anti HBs immunoglobulins.
Transplant procedures
Six adult patients and the 6-year-old child underwent
cadaveric whole LT, and two patients LRLT using a right
lobe. During all procedures, a continuous red cell saving
system was used to scavenge blood from the operative
field. As the liquid aspirated by the cell saving system is
a mixture of blood, ascitis and heparinized fluid from
the system itself, it is difficult to precisely determined
the operative bleeding (mean total aspirated fluid:
1472 ± 361 ml). The volume of red cell concentrate read-
ministrated to the patient during the operation, may be a
more objective estimation of the operative bleeding,
expressed as the amount of lost red cells (488 ± 115 ml
with 60% haematocrit). Mean graft ischaemia was
355 ± 47 min for cadaveric LT, and 42 min for LRLT.
Graft function was immediate in all cases, with intraoper-
ative bile production. No patient received any blood
product (except purified albumin when accepted) during
the surgical procedures.
Postoperative period
Postoperative day 1 mean haematocrit level was
30.8 ± 2.8% significantly lower than the pre transplant
level (P < 0.05), and further decreased during the post
transplant period (mean lowest haematocrit: 25.6 ± 3.1%,
P < 0.05). Mean haematocrit at discharge was
33.0 ± 2.3%.
Seven patients (patients no. 1–4, 6, 8 and 9) had no
severe complication during the whole hospitalization per-
iod. Their mean intensive care unit (ICU) stay was
4.0 days (range: 1–7 days), and they left the ward after a
mean postoperative stay of 21 days (range: 12–45 days).
Patient 3 denied the use of purified albumin. Her periop-
erative haemoglobin and albumin levels are presented in
Fig. 2. When she was suffering from deep hypoalbumine-
mia and hypoproteinemia she developed mild pleural
effusion. She did not need respiratory support and spon-
taneously recovered. She left ICU on postoperative day 7.
Two patients experienced severe complications. Patient
5, a 6-year-old girl, developed peritonitis secondary to
perforated gastric ulcer on day 6 and had to be reoperated.
Afterwards she developed inflammatory anaemia that did
not respond to erythropoietin and iron therapy. She
developed clinical symptoms of deep anaemia with severe
asthenia and tachypnea, and received one unit of red cells

























Figure 1 Evolution of platelet count before and after partial spleen
embolization in patients 1 and 6 (LT, liver transplantation; PSE, partial
spleen embolization; PW, post embolization week).
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16%. She improved rapidly and left the ward at postopera-
tive day 32. Patient 7, a CHILD C patient suffering from
HBV cirrhosis and hepatocarcinoma, underwent LRLT
with a right lobe harvested from his JW son, despite pre-
operative haematocrit level at 22.4%. During the proce-
dure total operative aspirated fluid was 3700 ml (1195 ml
reinjected). Postoperative haematocrit was 12.7%. Liver
graft function was immediate. However haematocrit fell to
8.2% at postoperative day 3. The patient’s family reques-
ted transfusion after cardiac arythmia episodes. The
patient developed invasive aspergillosis and died from
multiple organ failure at postoperative day 11. No right
lobe donor developed any complication or received any
blood product.
Follow-up
Four patients developed moderate rejection during hospi-
talization that was easily managed by increase of calcineu-
rin inhibitor levels and/or pulse of corticosteroids. Mean
follow-up was 41 months (ranges: 1–72 months). All
patients who survived the procedure were alive and well
at follow-up, with perfect liver graft function. Patient 1
developed HCV recurrence that was treated with inter-
feron and ribavirine with sustained viral response (normal
transaminases and negative PCR 6 months after end of
therapy). No other patients developed recurrence of the
preoperative disease. Patient 3 gave birth to a healthy
child 16 months after OLT.
Discussion
The JW population refuses transfusions of homologous
and autologous blood products that have been removed
from continuity with the body. This refusal is based on
their interpretation of the bible [1]. According to their
beliefs, acceptance of blood or blood products will forfeit
their chance for resurrection and eternal salvation. Most
JW accept crystalloid solutions, synthetic colloid solu-
tions, haemoglobin substitutes as perfluorocarbons or
artificial haemoglobin solutions, and recombinant pro-
teins as erythropoietin or activated factor VII, while
whole blood, red blood cells, platelets and plasma are
unacceptable. Individual decisions need to be made
regarding administration of purified fractions of plasma,
as immunoglobulins and albumin, or solid organ trans-
plants. Additionally, patients need to make personal deci-
sions regarding (heart or veno-venous) bypasses,
haemodilution and intraoperative red cell salvage. This
request may be challenging for physicians, as blood prod-
ucts may be life saving in some severe medical conditions.
On the contrary, the medical community has learned that
blood products may submit patients to some risk of life
threatening incidents [22], of allergic reactions, and of
various known (or unknown) blood-borne infections
[23]. It is also considered that multiple transfusions may
decrease immunity, and they have been linked to
increased postoperative morbidity and mortality rates
[24,25] and cancer recurrence [26]. These reasons, added
to the costs and the scarcity of some blood components,
have forced the development of blood product-free med-
ical strategies [27].
During the past decade, LT blood product requirements
have significantly decreased in most centres, coincidentally
with better patient and graft survival rates. This improve-
ment may be related to the better experience of the
medical teams with peri- operative liver recipient manage-
ment, to the better surgical techniques, to better LT indi-
cation and to better liver graft use and preservation. The
use of the antifibrinolytic agent aprotinin [28], of the lysin
analogues tranexamic acid and e-aminocaproic acid
[29,30] was also associated with decreased transfusion
requirements in LT. In a preliminay report, the use of
recombinant activated factor VII was also proposed to
reduce bleeding during LT [31]. The piggy-back technique
and the avoidance of veno-venous bypass, may allow less
transfusion requirements [32]. The use of autologous (cell
saver) transfusion in LT may increase the overall blood
transfusion requirement [33] but decreases the need of
allogeneic red blood cells from the blood bank [34].
In their usual adult LT practice, the authors routinely
use high dose aprotinin, autologous transfusion, and use
the LT technique described by Belghiti et al. [20]. This
piggy-back technique avoids the use of a veno-venous
bypass. The first steps of the procedure include the
ligature of the liver hilum elements but the portal
vein. Then, the completion of a systematic, large, tempor-
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Figure 2 Evolution of albumin and haemoglobin levels in patient 3
(NV, normal values; PD, postoperative day).
Liver transplantation in Jehovah’s witnesses Detry et al.
932 Transplant International 18 (2005) 929–936 ª 2005 European Society for Organ Transplantation
efficiently decompress the portal hypertension, and to
decrease the associated bleeding from the splanchnic bed.
To the authors’ view, the early devascularization of the
diseased liver reduces the bleeding associated with its
mobilization and dissection from the retrohepatic vena
cava, especially the bleeding from the accessory retro-
hepatic veins. The devascularized liver is also smaller,
mobile, and therefore easier to dissect. The piggy-back
technique also allows to limit bleeding and oozing from
the retro-caval space.
LRLT in adult recipients has been recently developed
to overcome the organ donor shortage [21]. LRLT may
be particularly interesting in JW patients, as it may allow
careful planning of the procedure at the best time for
both donors and recipients, and this is particularly crucial
in JW patients [13,15]. Moreover the quality of the graft
is perfect and ischaemic time is short, allowing immediate
graft function if the graft volume is sufficient. The most
experienced surgeons and anaesthesiologists may be all
present in the operative rooms. LRLT in JW patients may
be challenging if the donor is JW himself, as in one of
our cases (patient 7). It was recently demonstrated that in
right lobe donors, blood product transfusion is excep-
tional, especially as a cell saving system is systematically
used during surgical procedure [35]. So the authors, as
others, consider that LRLT may be proposed to JW
patients with a JW donor [16,36].
The authors considered the different means to prepare
JW patients for LT. Recombinant erythropoietin with oral
or intravenous iron supplementation, is an established,
efficient but relatively expensive therapy to increase
haematocrit levels and reduce allogeneic red blood cell
transfusion [37]. The use of recombinant human erythro-
poietin was also shown to raise the haematocrit concen-
tration in critically ill patients hospitalized in ICU, and to
reduce the number of units of red blood cells they require
[38]. In this study, the authors showed that it is possible
to significantly increase the haematocrit level in cirrhotic
patients waiting liver transplantation. Liver transplant
candidates also very often suffer from thrombocytopenia
induced by portal hypertension and hypersplenism. In
two cases of this series, the authors chose to perform par-
tial spleen embolization that allowed platelet count
increase [9]. Partial spleen embolization may present
severe complications, mainly sepsis by infection of the
necrotic splenic tissue, but may be efficient to increase
platelets in thrombocytopenia [19] that may last a few
weeks after the procedure. This temporary effect could be
a problem in case of long waiting time, but partial spleen
embolization could be helpful in preparation for LRLT.
Splenectomy may also be proposed [39], but this proce-
dure is more aggressive, may induce abdominal adhesions
and may be complicated by severe post transplant sepsis
[40]. Transjugular intrahepatic portosystemic shunt
(TIPS) may allow correction of portal hypertension in
cirrhotic patients, and may be associated with reduction
of intraoperative LT bleeding [41]. However, this finding
is largely disputed by other reports [42,43], and TIPS
does not increase the platelet level [44]. The authors
would not recommend systematic TIPS insertion in pre-
paration of JW for LT as it may decompensate liver func-
tion. They might discuss TIPS use in cirrhotic JW
transplant candidate with preserved liver function and
past history of major abdominal surgery (hepatobiliary,
gastric or colonic) in which vascularized adhesions may
render liver dissection haemorrhagic. However, the Uni-
versity of Southern California group reported successful
LRLT in JW patients who were prepared with TIPS [14].
Red cell saving by the mean of a device aspirating
blood from the surgical field, filtrating it and concentra-
ting the red cells for immediate autotransfusion, is gener-
ally accepted by JW if there is no interruption of the lines
between the device reservoir and the patient. Intraopera-
tive cell saving autotransfusion has been associated with
an increase in the overall blood loss in LT and an
increased need for overall blood transfusion [33], but the
need for allogeneic red cells is significantly decreased
[34]. The authors use intraoperative cell saving autotrans-
fusion in all LT cases. However, if autotransfusion allows
recovering of red cells and preserving haematocrit level,
platelets and coagulation factors are lost and that may be
a problem in case of significant acute intraoperative
bleeding. For coagulation cascade disturbances, the only
possible correction has to come from the liver graft itself,
as JW do not accept coagulation factors from human ori-
gin. This emphasizes the necessity of a perfect liver donor
and of short ischaemia for immediate graft function in
the setting of LT in JW. The recently developed recom-
binant activated factor VII may help to correct coagula-
tion in cirrhotic patients [45]. A preliminary study
showed some reduction in LT transfusion requirements
when recombinant activated factor VII is used at LT
induction [31]. The authors successfully used recombin-
ant activated factor VII during the adult-to-adult LRLT.
The main inconveniences of recombinant activated factor
VII are the high price and the potential hazards of hyper-
coagulation on fresh vascular sutures if used during LT.
However it may be the only way to partly correct the
coagulation disturbances in JW during or after LT.
Regarding other blood proteins, most JW accept the use
of purified human albumin. One of our patients did not
and suffered from severe hypoalbuminemia and hypopro-
teinemia that was well tolerated and corrected in a few
days.
As LT transfusion requirements have significantly
decreased and are no longer a problem for most blood
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banks, one may wonder if there is any interest and/or
need to further reduce allogeneic LT blood product
requirements in non JW patients. However, it is clear that
blood product transfusions submit patients to an added
risk of specific complications [24,27] and may have an
immunosuppressive effect [46,47] that may in part
explain the increased incidence of infectious complica-
tions in LT with important intraoperative loss [48], and
the lower patient and graft survival rates in patients who
require more than 10 units of packed red blood cells
[49]. On the contrary, LT recipients who receive low
quantity of blood products may be at higher risk of rejec-
tion of the liver graft, because of the decreased transfu-
sion-induced immunosuppression [48]. However, with
the improvement of the immunosuppressive protocols,
acute and/or chronic rejection is no longer a significant
source of patient and graft loss after LT. In this series, the
authors did not specifically study the effects of their pro-
tocol of allogeneic blood product avoidance in LT and
did not perform protocol liver graft biopsies because of
the risk of bleeding complications of liver biopsy. Four
patients had clinical and/or biopsy proven moderate acute
liver rejection that was treated with increased doses of
immunosuppressive drugs. Moreover, one may hypothes-
ize that the reduction of transfusion-induced immuno-
suppression may lead to a decreased risk of disease
recurrence after LT.
The main concern about offering LT to JW patients is
ethical. The acceptance of solid organ transplantation and
the refusal of transfusion are impossible to understand
for non-JW. It is clear that fully informed adult patients
have the right to refuse some therapy, as the use of blood
products. At the other hand health care personnel may
not accept this patient’s transfusion refusal. JW should
therefore be referred to teams experienced with bloodless
medical care that requires most often a multidisciplinary
approach. Every JW patient should be interviewed indi-
vidually, and the use of every blood fraction should be
discussed. External pressure has to be excluded. In our
experience one patient sent as JW for LT accepted trans-
fusion after private interview, pretending that her JW
husband pressured her to deny the use of blood product.
In the actual organ shortage era, cadaveric LT in JW rai-
ses another issue. The use of cadaveric liver grafts in JW
patients may only be justified if long-term results are equal
(or even better) than in the general LT population. The loss
of a JW patient because of bleeding during or after cadav-
eric LT would not only lose a human being, but a liver graft
that otherwise would have saved another patient who
would accept blood products. In this study, the authors
showed that prepared and selected JW might be transplan-
ted with equal results than the general population. No JW
patient receiving a cadaveric graft died. The authors believe
that long-term results of LT in JW patients might be excel-
lent, as these patients easily accept regular medical long-
term follow-ups. As a matter of fact, their high level of
beliefs might be a key to good results. It was reported that
in renal transplantation, recipients who use religious cop-
ing after transplantation appear to have a better outcome
than those who do not, may be by better postoperative
compliance [50]. In our series two JW patients underwent
living related LT, one with a JW donor. Living related LT
in JW has the advantage of not putting a cadaveric liver at
risk of bleeding. However living related LT with a JW
donor put a healthy donor at higher risk because of the
denial of use of blood products. This has to be considered
when such a procedure is planned [16].
In conclusion, the authors presented the results of a LT
program in JW patients. They demonstrated that it is
possible to increase haematocrit and platelet levels in cir-
rhotic patients waiting LT. With a multidisciplinary pro-
tocol, they were able to reduce the need of blood product
during LT procedures. This experience may be beneficial
for the general LT candidate population, as the use of
large amount of large amount of blood products during
LT have been linked to increased morbidity and mortality.
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